Brief: SynAct Pharma Q1 Sales SEK 0
27/05/2025 06:30
May 27 (Reuters) - SynAct Pharma Q1 adjusted EPS SEK -0.51. Q1 operating expenses SEK 28.098 million Q1 cash flow from operating activities SEK -28.826 million Q1 net income SEK -24.684 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development